Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBicycle Therapeutics Ltd

Bicycle Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.69 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
171799
Market Cap
358.29M

Momentum Score

…

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.67
Low
3.75
High
52 Week Price Range
4.24
Low
9.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bicycle Therapeutics is a clinical-stage biotech developing bicyclic peptide drugs intended to combine biologic selectivity with small-molecule size and tissue penetration. Growth drivers include advancing clinical candidates, expanding the platform to new targets and indications, and potential licensing or collaboration deals to extend development resources. Investors may find the company attractive for its platform-driven pipeline and potential clinical-stage milestones.
Key risks are clinical and regulatory failure, ongoing financing and dilution needs, and competition plus intellectual property uncertainty in peptide therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.69
Dividend Yield
-
Revenue TTM
72.59M
Revenue Per Share
1.05
Gross Profit TTM
-156.50M
Debt / Equity
0.03
ROE
-31.21%
Net Debt
-610.59M
ROCE
-42.88%
Diluted EPS TTM
-3.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -254.32M -173.80M -179.21M -114.24M -68.48M
Net income -218.96M -169.03M -180.66M -112.72M -66.82M
Selling general administrative 79.37M 71.46M 59.83M 49.51M 32.44M
Selling and marketing expenses - 0.72M - - -
Gross profit 72.59M -137.69M -129.52M 14.46M 11.70M
Reconciled depreciation 6.42M 7.17M 6.55M 3.69M 1.41M
Ebit -283.30M -172.07M -189.95M -116.65M -65.62M
Ebitda -276.86M -164.89M -183.40M -110.90M -65.50M
Depreciation and amortization 6.44M 7.18M 6.55M 5.76M 0.12M
Operating income -247.06M -209.87M -189.95M -116.65M -65.62M
Other operating expenses 356.05M 245.15M 216.92M 131.12M 77.31M
Interest expense 0.21M 1.73M 3.26M 3.34M 2.98M
Tax provision 0.15M -4.76M 1.46M -1.52M -1.66M
Interest income 28.46M 34.28M 14.00M 5.76M 0.12M
Net interest income 28.26M 32.55M 10.74M 2.41M -2.86M
Income tax expense 0.15M -4.76M 1.46M -1.52M -1.66M
Total revenue 72.59M 35.27M 26.98M 14.46M 11.70M
Total operating expenses 349.62M 72.18M 60.43M 131.12M 77.31M
Cost of revenue 6.44M 172.97M 156.50M - -
Total other income expense net 28.98M 36.08M 10.74M 2.41M -2.86M
Net income from continuing ops -218.96M -169.03M -180.66M -112.72M -66.82M
Net income applicable to common shares - - - -112.72M -66.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 717.60M 956.87M 595.34M 410.61M 479.79M
Other current assets -35.59M 13.43M 11.41M 9.02M 7.96M
Total liab 107.62M 163.81M 224.41M 139.83M 133.54M
Total stockholder equity 609.98M 793.06M 370.93M 270.78M 346.25M
Other current liab 44.56M 35.74M 26.63M 23.33M 11.86M
Common stock 0.89M 0.89M 0.55M 0.39M 0.38M
Capital stock 0.89M 0.89M 0.55M 0.39M 0.38M
Retained earnings -899.75M -680.79M -511.76M -331.10M -218.38M
Other liab - - - 45.28M 55.35M
Other assets - - - 8.46M 3.45M
Cash 628.11M 879.52M 526.42M 339.15M 438.68M
Total current liabilities 56.98M 67.23M 69.54M 53.34M 36.24M
Current deferred revenue - 10.19M 24.98M 20.42M 19.27M
Net debt -610.59M -870.03M -481.47M -294.83M -394.34M
Short term debt 2.76M 5.50M 4.88M 3.12M 2.38M
Short long term debt total 17.52M 9.49M 44.96M 44.33M 44.34M
Other stockholder equity 1512.34M 1472.84M 883.45M 601.11M 567.64M
Property plant equipment - - - 32.77M 17.79M
Total current assets 628.11M 928.61M 561.87M 369.38M 458.56M
Net tangible assets - - - 270.78M 346.25M
Net receivables 35.59M 35.65M 24.04M 21.21M 11.91M
Long term debt - - 30.70M 30.32M 29.87M
Accounts payable 9.67M 15.79M 13.05M 6.47M 2.72M
Accumulated other comprehensive income -3.50M 0.12M -1.30M 0.39M -3.39M
Non currrent assets other 89.43M 10.53M 5.25M 8.46M 3.45M
Non current assets total 89.49M 28.26M 33.48M 41.23M 21.24M
Capital lease obligations 16.85M 9.49M 14.26M 14.01M 14.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -1.24M -4.33M -18.99M -2.03M
Change to liabilities - - - 0.43M 38.31M
Total cashflows from investing activities -2.35M -1.24M -2.93M -18.99M -2.03M
Net borrowings -0.17M -31.91M 0.00M - 15.00M
Total cash from financing activities -0.13M 519.75M 250.03M 6.69M 320.73M
Change to operating activities - - - 1.89M -4.79M
Net income -218.96M -169.03M -180.66M -112.72M -66.82M
Change in cash -251.35M 353.10M 187.82M -99.53M 302.69M
Begin period cash flow 879.52M 526.97M 339.15M 438.68M 135.99M
End period cash flow 628.66M 880.07M 526.97M 339.15M 438.68M
Total cash from operating activities -249.68M -164.72M -60.63M -86.11M -14.79M
Issuance of capital stock 0.00M 544.13M 255.04M 5.70M 298.54M
Depreciation 6.42M 7.17M 6.55M 3.69M 1.41M
Other cashflows from investing activities 0.01M - - - -
Change to inventory - - -2.77M - -4.79M
Change to account receivables 2.90M -11.95M -1.20M -1.64M 4.54M
Other cashflows from financing activities -0.17M 7.53M 0.68M 0.99M 22.18M
Change to netincome - - - 22.25M 12.55M
Capital expenditures 2.36M 1.24M 2.93M 18.99M 2.03M
Change in working capital -75.93M -33.46M 76.66M 0.67M 38.06M
Stock based compensation 39.46M 38.08M 32.48M 26.78M 12.08M
Other non cash items 45.21M -2.26M 1.04M 0.44M 0.47M
Free cash flow -252.61M -165.96M -63.56M -105.10M -16.82M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BCYC
Bicycle Therapeutics Ltd		 -
-%		 3.69 - - 5.07 0.61 21.22 -2.14
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Bicycle Therapeutics Ltd

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Portway Building, Cambridge, United Kingdom, CB21 6GS

44 1223 261 503

https://www.bicycletherapeutics.com

288

Name Title Year Born
Dr. Kevin Lee M.B.A., Ph.D. CEO & Exec. Director 1969
Mr. Lee H. Kalowski M.B.A., MBA Pres & CFO 1981
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board 1951
Dr. Michael Skynner B.sc. Ph.d., Ph.D. Chief Technology Officer 1970
Dr. Christian Heinis Scientific Founder NA
Mr. Alistair Milnes Chief Operating Officer NA
Dr. Nicholas Keen Ph.D. Chief Scientific Officer 1968
Mr. David E. Borah CFA VP of Capital Markets & Investor Relations NA
Mr. Zafar Qadir Gen. Counsel NA
Dr. Gillian Langford Head of Clinical and Project Management NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…